Antje Tockhorn‐Heidenreich

Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial

Wim M. Mulleners, Byung‐Kun Kim, Miguel J. A. Láinez et al. · The Lancet Neurology · 2020 · 272 citations

Cluster Headache, Pharmacology, Clinical Trials +3

Factors associated with long-term impact on informal caregivers during Alzheimer’s disease dementia progression: 36-month results from GERAS

Catherine Reed, Mark Belger, J. Scott Andrews et al. · International Psychogeriatrics · 2019 · 61 citations · Full text

Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure

Dustin Ruff, Janet H. Ford, Antje Tockhorn‐Heidenreich et al. · Cephalalgia · 2019 · 39 citations

Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials

D. Ruff, James H. Ford, Antje Tockhorn‐Heidenreich et al. · European Journal of Neurology · 2019 · 39 citations · Full text

Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial

Uwe Reuter, Christian Lucas, David Doležil et al. · Advances in Therapy · 2021 · 34 citations · Full text